

World Journal of *Gastrointestinal Pharmacology and Therapeutics*

World J Gastrointest Pharmacol Ther 2015 February 6; 6(1): 1-9





Editorial Board

2011-2015

The *World Journal of Gastrointestinal Pharmacology and Therapeutics* Editorial Board consists of 411 members, representing a team of worldwide experts in surgery research. They are from 47 countries, including Argentina (3), Australia (13), Austria (4), Belarus (1), Belgium (3), Brazil (10), Canada (10), China (41), Czech Republic (1), Denmark (1), Egypt (3), Estonia (1), Finland (1), France (5), Germany (21), Greece (6), Hungary (4), India (18), Iran (6), Ireland (1), Israel (4), Italy (35), Japan (34), Lebanon (1), Lithuania (3), Mexico (2), Netherlands (10), New Zealand (2), Norway (2), Pakistan (2), Philippines (1), Poland (3), Portugal (2), Romania (1), Russia (1), Saudi Arabia (2), Singapore (3), Slovenia (1), South Africa (1), South Korea (16), Spain (13), Sweden (3), Switzerland (1), Thailand (4), Turkey (7), United Kingdom (20), and United States (84).

EDITOR-IN-CHIEF

Hugh J Freeman, *Vancouver*

STRATEGY ASSOCIATE

EDITORS-IN-CHIEF

Antonio Picardi, *Rome*

Elham Rahme, *Quebec*

Douglas Kevin Rex, *Indianapolis*

Angelo Zullo, *Rome*

GUEST EDITORIAL BOARD

MEMBERS

Full-Young Chang, *Taipei*

Mei-Chi Chang, *Taoyuan*

Ming-Jen Chen, *Taipei*

Chia-Yen Dai, *Kaohsiung*

Jiiang-Huei Jeng, *Taipei*

Wun-Chang Ko, *Taipei*

Hwai Jeng Lin, *Changhua*

Ming-Yie Liu, *Tainan*

Frank C Mao, *Taichung*

Tzu-Ming Pan, *Taipei*

Bor-Shyang Sheu, *Tainan*

Li Hsueh Tsai, *Taipei*

Keng-Liang Wu, *Kaohsiung*

Being-Sun Wung, *Chiayi*

Hsu-Heng Yen, *Changhua*

MEMBERS OF THE EDITORIAL BOARD



Argentina

Viviana Alicia Catania, *Rosario*

Guillermo Daniel Mazzolini, *Derqui-Pilar*

Valeria Paula Tripodi, *Buenos Aires*



Australia

Noor Al-Dasooqi, *Adelaide*

Thomas J Borody, *Sydney*

Rachel Jane Gibson, *Adelaide*

Xu-Feng Huang, *Wollongong*

Eline Suzanne Klaassens, *St Lucia*

Natasha A Koloski, *Brisbane*

Ian Lawrance, *Fremantle*

John Martin Mariadason, *Victoria*

Antonina Mikocka-Walus, *Melbourne*

Tim Murphy, *Adelaide*

Nam Quoc Nguyen, *Adelaide*

Samir Samman, *Sydney*

Neville D Yeomans, *Penrith South*



Austria

Martin Brunner, *Vienna*

Sonja Fruhwald, *Graz*

Michael Trauner, *Graz*

Viktoria Weber, *Krems*



Belarus

Sergey I Pimanov, *Vitebsk*



Belgium

Monika Schöller-Gyüre, *Mechelen*

Kristin Verbeke, *Leuven*

Vandenplas Yvan, *Alsemberg*



Brazil

Andréia Buffon, *Porto Alegre*

Gabriela Villaça Chaves, *Rio de Janeiro*

Percília Cardoso Gaiquinto, *Botucatu*

Clelia Akiko Hiruma-Lima, *Botucatu*

Andre Castro Lyra, *Bahia*

Edson Marchiori, *Rio de Janeiro*

Ricardo de Souza Pereira, *Macapá*

Rafael Roesler, *Porto Alegre*

Leonardo Lucca Schiavon, *Florianópolis*

Francisca Cléa Florenço Sousa, *Fortaleza*



Canada

Brian Bressler, *Vancouver*

Yuewen Gong, *Manitoba*

Hien Quoc Huynh, *Edmonton*

Grigorios I Leontiadis, *Hamilton*

Sharon Marsh, *Québec*

Jean Sévigny, *Québec*

Martin Alexander Storr, *Alberta*

John Thomas Weber, *St. John's*



China

Zhao-Xiang Bian, *Hong Kong*

Xin-Jing Chen, *Nanjing*

Chi-Hin Cho, *Hong Kong*

Yong-Song Guan, *Chengdu*

Zhi-Li Huang, *Shanghai*

Bo Li, *Beijing*

Duo Li, *Hangzhou*

Yu-Yuan Li, *Guangzhou*

Xiong Ma, *Shanghai*
 Pan Qin, *Shanghai*
 Guo-Ping Sun, *Hefei*
 Xue-Ying Sun, *Harbin*
 Ming-Fu Wang, *Hong Kong*
 Che-Yuen Justin Wu, *Hong Kong*
 De-Xiang Xu, *Hefei*
 Rui-An Xu, *Xiamen*
 Ming-Xian Yan, *Jinan*
 Yong-Feng Yang, *Nanjing*
 Thomas Yau, *Hong Kong*
 Win-Nei Yeo, *Hong Kong*
 Long Yu, *Guangzhou*
 Jian-Ping Yuan, *Guangzhou*
 Man-Fung Yuen, *Hong Kong*
 Jian-Fu Zhang, *Xuzhou*
 Li-Qun Zhang, *Beijing*
 Min-Sheng Zhu, *Nanjing*



Czech Republic

Rene Kizek, *Brno*



Denmark

Ole Haagen Nielsen, *Herlev*



Egypt

Omar Mohamed Abdel-Salam, *Cairo*
 Ahmed Osman Abdel-Zaher, *Assiut*
 Osama Ahmed Badary, *Cairo*



Estonia

Riin Tamm, *Tartu*



Finland

Riitta Korpela, *Helsinki*



France

Ferrand Audrey, *Toulouse*
 Frederic Batteux, *Paris*
 Thierry Capiod, *Paris*
 Frederic Lagarce, *Angers*
 Hang Thi Thu Nguyen, *Clermont-Ferrand*



Germany

Susanne Beckebaum, *Essen*
 Jürgen Borlak, *Hannover*
 Güralp Onur Ceyhan, *Munich*
 Walee Chamulitrat, *Heidelberg*
 Anton Gillessen, *Muenster*
 Dirk Heitzmann, *Muenster*
 Jens Michael Heyn, *München*
 Joachim Labenz, *Siegen*
 Florian Lang, *Tübingen*
 Klaus Mönkemüller, *Bottrop*
 Thomas Müller, *Berlin*
 Belal Naser, *Salzgitter*

Beate Niesler, *Heidelberg*
 Matthias Ocker, *Marburg*
 Andreas Marc Palmer, *Konstanz*
 Dirk Rades, *Lubeck*
 Fuat Hakan Saner, *Essen*
 Manfred V Singer, *Mannheim*
 Konrad Ludwig Streetz, *Aachen*
 Frank Tacke, *Aachen*
 Gerhard Treiber, *Balingen*



Greece

Moses Elisaf, *Ioannina*
 Anastasios Koulaouzidis, *Greek*
 Ioannis E Koutroubakis, *Crete*
 Spilios Manolakopoulos, *Athens*
 Konstantinos C Mountzouris, *Athens*
 George Papatheodoridis, *Athens*



Hungary

Zsolt Barta, *Debrecen*
 László Czakó, *Szeged*
 Béla Molnár, *Budapest*
 Gyula Mózsik, *Pecs*



India

Anil Kumar Agarwal, *New Delhi*
 Sandip Basu, *Bombay*
 Chiranjib Chakraborty, *Vellore*
 Rukhsana Chowdhury, *Kolkata*
 Santosh Darisetty, *Hyderabad*
 C M Habibullah, *Andhra Pradesh*
 Mohammad Sultan Khuroo, *Kashmir*
 Mohandas K Mallath, *Mumbai*
 Balraj Mittal, *Lucknow*
 Rama Devi Mittal, *Lucknow*
 Asish Kumar Mukhopadhyay, *Kolkata*
 Lekha Saha, *Chandigarh*
 Shiv Kumar Sarin, *New Delhi*
 Jayshri Ankur Shah, *Mumbai*
 Sonu Sundd Singh, *Gurgaon*
 Sikta Swarnakar, *Kolkata*
 Rakesh Tandon, *New Delhi*
 Asna Urooj, *Mysore*



Iran

Seyed Mohsen Dehghani, *Shiraz*
 Ahmad Reza Dehpour, *Tehran*
 Sara Farhang, *Tabriz*
 Ali Gholamrezaei, *Isfahan*
 Parisa Hasanein, *Hamadan*
 Amir Mohammad Mortazavian, *Tehran*



Ireland

Zaid Heetun, *Kilkenny*



Israel

Nimer Najib Assy, *Safed*

Rami Eliakim, *Haifa*
 Simon Bar Meir, *Hashomer*
 Haim Shmuel Odes, *Beer Sheba*



Italy

Giovanni C Actis, *Torino*
 Pietro Andreone, *Bologna*
 Bruno Annibale, *Rome*
 Leonardo Baiocchi, *Rome*
 Giovanni Barbara, *Bologna*
 Gabrio Bassotti, *Perugia*
 Francesca Borrelli, *Naples*
 Giuseppe Brisinda, *Rome*
 Renzo Caprilli, *Rome*
 Mauro Antonio Maria Carai, *Cagliari*
 Renato Caviglia, *Rome*
 Carolina Ciacci, *Naples*
 Mario Cottone, *Trabucco*
 Roberto De Giorgio, *Bologna*
 Luca Elli, *Milano*
 Alessandro Granito, *Bologna*
 Francesco William Guglielmi, *Trani*
 Mario Guslandi, *Milan*
 Pietro Invernizzi, *Rozzano*
 Mariano Malaguarnera, *Catania*
 Gianpiero Manes, *Milano*
 Massimo C Mauri, *Milan*
 Massimo Montalto, *Rome*
 Giovanni Monteleone, *Rome*
 Gerardo Nardone, *Napoli*
 Fabio Pace, *Milano*
 Raffaele Pezzilli, *Bologna*
 Rita Rezzani, *Brescia*
 Carmelo Scarpignato, *Parma*
 Generoso Uomo, *Napoli*
 Paolo Usai-Satta, *Cagliari*
 Maurizio Vecchi, *Milano*
 Massimiliano Veroux, *Catania*



Japan

Akira Andoh, *Otsu*
 Yuichiro Eguchi, *Saga*
 Munechika Enjoji, *Fukuoka*
 Norihiro Furusyo, *Fukuoka*
 Naoki Hotta, *Aichi*
 Shigeo Ikegawa, *Higashi-Osaka*
 Susumu Ito, *Okinawa*
 Satoru Kakizaki, *Gunma*
 Terumi Kamisawa, *Tokyo*
 Motoyori Kanazawa, *Sendai*
 Takuma Kato, *Mie*
 Takashi Kawai, *Tokyo*
 Shirao Kuniaki, *Oita*
 Nobuyuki Matsushashi, *Tokyo*
 Tatsuya Matsura, *Yonago*
 Teruo Murakami, *Hiroshima*
 Yuji Naito, *Kyoto*
 Katsuyuki Nakajima, *Maebashi Gunma*
 Hiroshi Nakase, *Kyoto*
 Nobuhiro Ohkohchi, *Tsukuba*
 Shogo Ohkoshi, *Niigata City*
 Tomohiko Shimatani, *Hiroshima*
 Yasuhiko Sugawara, *Tokyo*
 Yoshitaka Takuma, *Okayama*
 Tatsuhiro Tsujimoto, *Nara*
 Takato Ueno, *Kurume*
 Kenji Watanabe, *Osaka*

Toshiaki Watanabe, *Tokyo*
 Jiro Watari, *Nishinomiya*
 Satoshi Yamagiwa, *Niigata*
 Takayuki Yamamoto, *Mie*
 Norimasa Yoshida, *Kyoto*
 Hitoshi Yoshiji, *Nara*
 Katsutoshi Yoshizato, *Hiroshima*



Lebanon

Ala Sharara, *Beirut*



Lithuania

Dalia Adukauskienė, *Kaunas*
 Giedrius Barauskas, *Kaunas*
 Laimas Virginijus Jonaitis, *Kaunas*



Mexico

Pablo Muriel, *Mexico City*
 Guillermo B Robles-Díaz, *Mexico City*



Netherlands

Judith Elisabeth Baars, *Rotterdam*
 Albert J Bredenoord, *Nieuwegein*
 Nanne KH de Boer, *Amsterdam*
 Pieter Jan Floris de Jonge, *Rotterdam*
 Wouter J de Jonge, *Amsterdam*
 Mireille A Edens, *Groningen*
 Chris Mulder, *Amsterdam*
 Godefridus Johannes Peters, *Amsterdam*
 Paul E Sijens, *Groningen*
 Vera Esther Valkhoff, *Rotterdam*



New Zealand

Momir M Mikov, *Dunedin*
 Maxim Petrov, *Auckland*



Norway

Guanglin Cui, *Tromsø*
 Reidar Fossmark, *Trondheim*



Pakistan

Furqaan Ahmed, *Karachi*
 Anwar Hassan Gilani, *Karachi*



Philippines

Mark Anthony De Lusong, *Quezon City*



Poland

Halina Cichoz-Lach, *Lublin*
 Jarosław Czyż, *Cracow*
 Julian Teodor Swierczynski, *Gdansk*



Portugal

Cristina Freire, *Hull*
 Ana Isabel Gouveia Lopes, *Lisbon*



Romania

Dan Lucian Dumitrascu, *Cluj*



Russia

Tatyana A Korolenko, *Novosibirsk*



Saudi Arabia

Moamen Salah Refat, *Taif*
 Shahab Uddin, *Riyadh*



Singapore

Kok-Ann Gwee, *Singapore*
 Khek-Yu Ho, *Singapore*
 Kok-Yuen Ho, *Singapore*



Slovenia

Rok Orel, *Ljubljana*



South Africa

C Johannes van Rensburg, *Tygerberg*



South Korea

Chong-Su Cho, *Seoul*
 Ki Baik Hahm, *Incheon*
 Seok Joo Han, *Seoul*
 Jeong Won Jang, *Incheon*
 Dong Joon Kim, *Chuncheon*
 Jae J Kim, *Seoul*
 Kyoung Mee Kim, *Seoul*
 Nayoung Kim, *Gyeonggi-do*
 Sung-Bae Kim, *Seoul*
 Byung-Hoon Lee, *Seoul*
 Kwan Sik Lee, *Seoul*
 Sang-Han Lee, *Daegu*
 Yun Jeong Lim, *Kyunggi-do*
 Ji-Young Park, *Seoul*
 Uy Dong Sohn, *Seoul*
 Young-Joon Surh, *Seoul*



Spain

Matias Antonio Avila, *Pamplona*
 Luis Bujanda, *San Sebastián*
 Maria Carmen Collado, *Paterna*
 Conrado M Fernandez-Rodriguez, *Madrid*
 Ángel Lanas, *Zaragoza*
 Juan-R Malagelada, *Barcelona*
 Jose JG Marin, *Salamanca*

Antonio Ruiz Medina, *Jaén*
 Maria J Monte, *Salamanca*
 Miguel Muñoz, *Seville*
 Jesus Prieto, *Pamplona*
 Victor Manuel Victor, *Valencia*
 Maria D Yago, *Granada*



Sweden

Bodil Ohlsson, *Malmö*
 Henrik Thorlacius, *Malmö*
 Curt Tysk, *Örebro*



Switzerland

Carsten Alexander Wagner, *Zurich*



Thailand

Weekitt Kittisupamongkol, *Bangkok*
 Abhasnee Sobhonslidsuk, *Bangkok*
 Suporn Treepongkaruna, *Bangkok*
 Sombat Treeprasertsuk, *Bangkok*



Turkey

Fusun Acarturk, *Etiler-Ankara*
 Engin Altintas, *Mersin*
 Gül Deniz Karadeniz Cakmak, *Zonguldak*
 Hayrullah Derici, *Balıkesir*
 Mukaddes Eşrefoğlu, *Malatya*
 Ilker Tasci, *Etilik*
 Berrak Çağlayan Yeğen, *Haydarpaşa*



United Kingdom

Nadeem Ahmad Afzal, *Hampshire*
 Qasim Aziz, *London*
 Hugh BARR, *Gloucester*
 Ian Leonard Phillip Beales, *Norwich*
 Barbara Braden, *Oxford*
 Susan J Duthie, *Aberdeen*
 Eyad Elkord, *Manchester*
 Anton Vignaraj Emmanuel, *London*
 Konstantinos C Fragkos, *London*
 Nusrat Husain, *Cheshire*
 Jin-Yong Kang, *London*
 Mariusz Madalinski, *Ipswich*
 Srinivasan Madhusudan, *Nottingham*
 Subramanian Mahadevan, *Birmingham*
 John Francis Mayberry, *Leicester*
 Chuka Uche Nwokolo, *Coventry*
 Ajith Kumar Siriwardena, *Manchester*
 Her-Hsin Tsai, *Cottingham*
 Konstantinos Tziomalos, *London*
 Craig LC Williams, *Glasgow*



United States

Zubair H Aghai, *Camden*
 Shrikant Anant, *Oklahoma City*
 Kondala R Atkuri, *Stanford*
 Cheryl Hunt Baker, *Orlando*
 James M Becker, *Boston*

Qiang Cai, *Atlanta*
 Jiande Chen, *Galveston*
 Liang Cheng, *Indianapolis*
 Joan Clària, *Boston*
 Seth D Crockett, *Chapel Hill*
 Joseph John Cullen, *Iowa*
 Brian J Day, *Colorado*
 Cataldo Doria, *Philadelphia*
 Craig Stephen Dorrell, *Portland*
 Douglas Arnold Drossman, *Chapel Hill*
 Eli D Ehrenpreis, *Illinois*
 Bing-Liang Fang, *Houston*
 Ronnie Fass, *Arizona*
 S Hossein Fatem, *Minneapolis*
 Linda A Feagins, *Dallas*
 Mitchell P Fink, *Los Angeles*
 Lori Fischbach, *Fort Worth*
 Craig Alan Friesen, *Kansas City*
 Fie Gao, *Bethesda*
 M Eric Gershwin, *Davis*
 Shannon Stroud Glaser, *Temple*
 Stephen A Harrison, *Fort Sam Houston*
 Hendrik Heinz, *Ohio*
 Tiberiu Hershcovici, *Tucson*
 Weihong Hou, *Charlotte*
 Peng Huang, *Houston*

William Moses Huang, *New York*
 William Jeffrey Hurst, *Hershey*
 Hartmut Jaeschke, *Kansas City*
 Robert T Jensen, *Bethesda*
 David A Johnson, *Norfolk*
 Pramodini B Kale-Pradhan, *Detroit*
 Vik Khoshoo, *Marrero*
 Tammy L Kindel, *Cincinnati*
 Nils Lambrecht, *California*
 Joel Edward Lavine, *New York*
 Lorenzo Leggio, *Providence*
 Felix W Leung, *North Hills*
 Josh Levitsky, *Chicago*
 Robert W Li, *Washington*
 Allen W Mangel, *Research Triangle Park*
 Richard A Marlar, *Oklahoma City*
 Craig J McClain, *Louisville*
 Murielle Mimeault, *Omaha*
 Smruti R Mohanty, *Chicago*
 John Edward Morley, *St. Louis*
 Sandeep Mukherjee, *Omaha*
 Michael Foster Olive, *Charleston*
 Keith M Olsen, *Omaha*
 Virendra N Pandey, *Newark*
 Narasimham Laxmi Parinandi, *Columbus*
 William Parker, *Durham*

Paul J Pockros, *La Jolla*
 Suofu Qin, *Irvine*
 P Hemachandra Reddy, *Oregon*
 Randolph Eldon Regal, *Ann Arbor*
 Jean-François Rossignol, *Tampa*
 Leonard P Rybak, *Springfield*
 George Sachs, *Los Angeles*
 M Wasif Saif, *New Haven*
 Bimaljit Singh Sandhu, *Richmond*
 Bo Shen, *Cleveland*
 Ashwani Kumar Singal, *Rochester*
 Biographical Sketch, *Hershey*
 Bronislaw Slomiany, *Newark*
 Charles Jeffrey Smith, *Columbia*
 Shi-Yong Sun, *Atlanta*
 Kenneth J Vega, *Oklahoma City*
 Yu-Jui Yvonne Wan, *Kansas*
 Lixin Wang, *Los Angeles*
 Horst Christian Weber, *Boston*
 Brian Wigdahl, *Philadelphia*
 Guang-Yin Xu, *League City*
 Yoshio Yamaoka, *Houston*
 Yutao Yan, *Atlanta*
 Jieyun Yin, *Galveston*
 Jian-Min Yuan, *Minnesota*
 Jian-Ying Zhang, *El Paso*



MINIREVIEWS

- 1 Prevention of pelvic radiation disease

Fuccio L, Frazzoni L, Guido A

Contents

World Journal of Gastrointestinal Pharmacology and Therapeutics

Volume 6 Number 1 February 6, 2015

ABOUT COVER

Editorial Board Member of *World Journal of Gastrointestinal Pharmacology and Therapeutics*, Jürgen Borlak, Professor, Hannover Medical School, Center for Pharmacology and Toxicology, Institute of Pharmaco-and Toxikogenomikforschung, OE 9646, Carl-Neuberg-Str.1, Hannover 30625, Germany

AIM AND SCOPE

World Journal of Gastrointestinal Pharmacology and Therapeutics (*World J Gastrointest Pharmacol Ther*, *WJGPT*, online ISSN 2150-5349, DOI: 10.4292), is a peer-reviewed open access academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

WJGPT covers topics concerning: (1) Clinical pharmacological research articles on specific drugs, concerning with pharmacodynamics, pharmacokinetics, toxicology, clinical trial, drug reactions, drug metabolism and adverse reaction monitoring, *etc.*; (2) Research progress of clinical pharmacology; (3) Introduction and evaluation of new drugs; (4) Experiences and problems in applied therapeutics; (5) Research and introductions of methodology in clinical pharmacology; and (6) Guidelines of clinical trial.

We encourage authors to submit their manuscripts to *WJGPT*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great basic and clinical significance.

INDEXING/ ABSTRACTING

World Journal of Gastrointestinal Pharmacology and Therapeutics is now indexed in PubMed Central, PubMed, Digital Object Identifier, and Directory of Open Access Journals.

FLYLEAF

I-IV Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xiang Li*
Responsible Electronic Editor: *Ya-Jing Lu*
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Xue-Mei Gong*
Proofing Editorial Office Director: *Xin-Xia Song*

NAME OF JOURNAL

World Journal of Gastrointestinal Pharmacology and Therapeutics

ISSN

ISSN 2150-5349 (online)

LAUNCH DATE

May 6, 2010

FREQUENCY

Quarterly

EDITOR-IN-CHIEF

Hugh J Freeman, MD, FRCPC, FACP, Professor,
Department of Medicine (Gastroenterology), University of British Columbia, Hospital, 2211 Wesbrook Mall, Vancouver, BC V6T1W5, Canada

EDITORIAL OFFICE

Jin-Lei Wang, Director
Xiu-Xia Song, Vice Director

World Journal of Gastrointestinal Pharmacology and Therapeutics

Room 903, Building D, Ocean International Center,
No. 62 Dongsihuan Zhonglu, Chaoyang District,
Beijing 100025, China
Telephone: +86-10-85381891
Fax: +86-10-85381893
E-mail: editorialoffice@wjgnet.com
Help Desk: <http://www.wjgnet.com/esps/helpdesk.aspx>
<http://www.wjgnet.com>

PUBLISHER

Baishideng Publishing Group Inc
8226 Regency Drive,
Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.wjgnet.com/esps/helpdesk.aspx>
<http://www.wjgnet.com>

PUBLICATION DATE

February 6, 2015

COPYRIGHT

© 2015 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT

All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS

Full instructions are available online at http://www.wjgnet.com/2150-5349/g_info_20100315084234.htm

ONLINE SUBMISSION

<http://www.wjgnet.com/esps/>

Prevention of pelvic radiation disease

Lorenzo Fuccio, Leonardo Frazzoni, Alessandra Guido

Lorenzo Fuccio, Leonardo Frazzoni, Department of Medical and Surgical Sciences, S.Orsola-Malpighi Hospital, University of Bologna, 40136 Bologna, Italy.

Alessandra Guido, Division of Radiation Oncology, S.Orsola-Malpighi Hospital, University of Bologna, 40136 Bologna, Italy

Author contributions: All the authors equally contributed to the paper and approved the final version of the article.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Correspondence to: Lorenzo Fuccio, MD, Department of Medical and Surgical Sciences, S.Orsola-Malpighi Hospital, University of Bologna, Via Massarenti 9, 40136 Bologna, Italy. lorenzofuccio@gmail.com

Telephone: +39-51-6363338

Fax: +39-51-6363338

Received: June 6, 2014

Peer-review started: June 8, 2014

First decision: July 10, 2014

Revised: September 2, 2014

Accepted: November 7, 2014

Article in press: November 10, 2014

Published online: February 6, 2015

Abstract

Pelvic cancers are among the most frequently diagnosed cancers worldwide. Treatment of patients requires a multidisciplinary approach that frequently includes radiotherapy. Gastrointestinal (GI) radiation-induced toxicity is a major complication and the transient or long-term problems, ranging from mild to very severe, arising in non-cancerous tissues resulting from radiation treatment to a tumor of pelvic origin, are actually called as pelvic radiation disease. The incidence of pelvic radiation disease changes according to the radiation technique, the length of follow up, the assessment

method, the type and stage of cancer and several other variables. Notably, even with the most recent radiation techniques, *i.e.*, intensity-modulated radiotherapy, the incidence of radiation-induced GI side effects is overall reduced but still not negligible. In addition, radiation-induced GI side effects can develop even after several decades; therefore, the improvement of patient life expectancy will unavoidably increase the risk of developing radiation-induced complications. Once developed, the management of pelvic radiation disease may be challenging. Therefore, the prevention of radiation-induced toxicity represents a reasonable way to avoid a dramatic drop of the quality of life of these patients. In the current manuscript we provide an updated and practical review on the best available evidences in the field of the prevention of pelvic radiation disease.

Key words: Pelvic radiation disease; Radiotherapy; Gastrointestinal toxicity; Amifostine; Aminosaliclates; Sucralfate; Beclomethasone dipropionate; Probiotics supplementation; Misoprostol; Mesalazine

© **The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Radiotherapy is a treatment of choice in the management of several pelvic cancers. Acute and late-onset radiation-induced gastrointestinal toxicity, also known as pelvic radiation disease, is still frequently observed, despite recent improvements in radiation techniques. In the current review we provide an updated overview on the medical therapies that have been investigated with preventive intents, focusing our attention on the best available evidences, primarily randomized controlled studies.

Fuccio L, Frazzoni L, Guido A. Prevention of pelvic radiation disease. *World J Gastrointest Pharmacol Ther* 2015; 6(1): 1-9 Available from: URL: <http://www.wjgnet.com/2150-5349/full/v6/i1/1.htm> DOI: <http://dx.doi.org/10.4292/wjgpt.v6.i1.1>

INTRODUCTION

Pelvic cancers are among the most frequently diagnosed cancers worldwide^[1]. Treatment of patients requires a multidisciplinary approach that frequently includes radiotherapy. Healthy intestinal tissue, mainly from distal large bowel and loops of the small intestine, is usually encompassed in the radiation field during radiotherapy for pelvic and abdominal tumors. Gastrointestinal (GI) radiation-induced toxicity is a major complication and the transient or long-term problems, ranging from mild to very severe, arising in non-cancerous tissues resulting from radiation treatment to a tumor of pelvic origin, are actually called as pelvic radiation disease (PRD)^[2]. The incidence of PRD changes according to the radiation technique, the length of follow up, the assessment method, the type and stage of cancer and several other variables^[3]. Notably, even with the most recent radiation techniques, *i.e.*, intensity-modulated radiotherapy, the incidence of radiation-induced GI side effects is overall reduced but still not negligible. In the last decade, the implementation of radiation techniques able to deliver higher radiation dose to the tumour mass and sparing the surrounding normal tissue have reduced the incidence of acute radiation-induced toxicities^[4]. However, larger volumes of normal tissues receive low doses of radiation compared to conventional treatment, *i.e.*, 3D conformal radiotherapy, and the effect of combined chemotherapy and radiotherapy in sensitizing normal tissues to long-term effects are yet largely unknown. In addition, radiation-induced gastrointestinal side effects can develop even after several decades; therefore, the improvement of patient life expectancy will unavoidably increase the risk of developing radiation-induced complications.

Several patient-related risk factors have been identified: diabetes, inflammatory bowel diseases (Crohn's disease and ulcerative colitis) and collagen vascular diseases (scleroderma, systemic lupus erythematosus)^[3]. All these risk factors represent independent predictor of both acute and late-onset pelvic radiation disease^[3]. Tobacco smoking and a body mass index less than 18.5 kg/m² increase the risk of developing radiation-induced side effects^[3].

Once developed, the management of pelvic radiation disease may be challenging, due to the scarce treatment options and the almost lack of robust and well-performed interventional prospective studies^[3]. Radiation toxicity is defined as acute when it occurs during radiotherapy or within 3 mo after treatment, while it is defined as chronic when it develops after longer time periods. The most frequent radiation-related side effects are diarrhea, urgency, rectal bleeding, and fecal incontinence, reported in about 5%-50% of patients^[3,5,6]. Therefore, the prevention of radiation-induced toxicity represents a reasonable way to avoid a dramatic drop of the

quality of life of these patients.

Aim of the current manuscript is to provide an updated and practical review on the best available evidences in the field of the prevention of pelvic radiation disease.

PATHOGENESIS

The pathogenesis of pelvic radiation disease is complex and includes changes in most sections of the colo-rectal wall. In the acute phase, during and soon after irradiation, mucosal injuries become clear and are primarily the result of apoptotic processes in the crypt epithelium, breakdown of the mucosal barriers and inflammation, thus altering the mucosal permeability. When the mucosal barrier becomes interrupt, bacterial products and other activating and potentially toxic agents, gain access to sub-epithelial intestinal tissue, where they stimulate a variety of immune cells to produce cytokines and other pro- and anti-inflammatory mediators^[7,8]. In the late-onset phase, prominent structural changes include atrophy of the mucosa, fibrosis of the intestinal wall, and vascular sclerosis. Radiation-induced endothelial dysfunction leads to loss of thrombo-resistance, resulting in thrombin formation, neutrophil recruitment and activation, and stimulation of mesenchymal cells^[7-10]. Thus, the typical chronic aspects are represented by diffuse connective tissue fibrosis, obliterative endoarteritis and following neo-angiogenesis with telangiectasias development. Therefore, the development of late-onset, chronic radiation-induced symptoms are strictly related to the fibrotic and ischemic process and to the chronic state of inflammation and alteration of the gut permeability and barrier function.

DRUGS FOR PREVENTING PRD

In the last decades several drugs have been investigated as potential chemopreventive agents (Table 1); in the next paragraphs we will provide a brief overview on these drugs, focusing on the best available evidences and on the effects on both acute and late-onset radiation-induced side effects.

Amifostine

Amifostine is an organic thiophosphate cytoprotective agent^[11]. The rationale for the use of amifostine as a radioprotective agent is its capability of detoxifying the reactive metabolites and scavenging reactive oxygen species generated by tissue irradiation. The selective action of amifostine on normal instead of tumoural tissue is attributed to the higher capillary alkaline phosphatase activity, higher pH and better vascularity of normal tissues compared to tumour tissue, resulting in a more rapid generation of the active thiol metabolite^[12].

Table 1 Efficacy of drugs as possible preventive agents of pelvic radiation disease

Drug	Route of administration	Type of evidence	Prevention		Comments
			Acute PRD	Chronic PRD	
Amifostine	IV or SC	RCTs	Yes	No	A dose of 340 mg/m ² IV or 500 SC administered during the whole period of treatment may prevent acute but not late-onset symptoms Nausea and vomiting are common side effects
Amifostine	Rectal	RCTs	Yes	?	Intrarectal administration is feasible and seems safe A dose of 1–2 g/d administered during the whole period of treatment may prevent acute symptoms A dose of 2 g/d seems more effective than 1 g/d No systemic side effects reported No definitive data on long-term effect Large multicenter RCTs are warranted
Sulfasalazine	Oral	RCT	Yes	?	A dose of 1000 mg/d significantly reduces the risk of developing diarrhea during radiation treatment
Balsalazide	Oral	RCT	Yes	No	Daily dose of 6 capsules may reduce compliance to the preventive treatment in clinical practice Possible beneficial effect Large multicenter RCTs are warranted
Mesalazine	Oral or rectal	RCTs	No	?	No beneficial or even harmful effects on acute symptoms
Beclomethasone	Rectal	RCT	No	Yes	Possible preventive effect on late-onset rectal bleeding and cost-effective preventive strategy
Sucralfate	Oral	RCTs	No	No	No beneficial or even harmful effect as preventive agents on both acute and late-onset symptoms
Probiotics	Oral	RCTs Meta-analysis	Yes	?	Useful for treating rectal bleeding Large multicenter RCTs are warranted

IV: Intravenous; SC: Subcutaneous; RCT: Randomized controlled trial; PRD: Pelvic radiation disease.

Amifostine can be administered intravenously, subcutaneously or intrarectally. Several randomized controlled trials have investigated the efficacy of amifostine treatment for the prevention of pelvic radiation disease^[13–19].

Effect on acute PRD: Overall, amifostine preventive treatment has shown to be effective in the prevention of acute, early-onset radiation-induced disease, particularly when administered intrarectally^[13].

Athanassiou *et al.*^[14] enrolled 205 patients with pelvic cancer, 110 treated with daily intravenous amifostine (340 mg/m² in 3–5 min, 15–30 min before RT) and 95 controls. Grade 2–3 acute toxicity, according to the EORTC/RTOG clinical scale, was reported in 5.5% of patients in the amifostine group against 22.1% in the control group ($P = 0.001$). Katsanos *et al.*^[15] demonstrated in a randomized controlled trial that the subcutaneous administration of amifostine was feasible and effective. Forty-four patients with either rectal or uterine cancer were enrolled: 21 patients were assigned to the active arm (daily s.c. amifostine at a dose of 500 mg, 20–30 min before radiotherapy) and 23 were randomized to the control group. Four patients (17.4%) in the control group developed acute colitis whilst none of the patients in the active group developed acute colitis ($P = 0.05$)^[15].

In order to increase patient compliance and acceptance, the intrarectal route has been

investigated as an alternative to the intravenous or subcutaneous routes. Kouloulis *et al.*^[16] in a randomized controlled trial evaluated 67 patients, 33 of whom were treated with daily intrarectal amifostine at a dose of 1.5 g administered as an aqueous solution in a 40-mL enema vs 34 controls and found that amifostine treatment significantly reduced acute rectal toxicity from 44% (Grades I–II) to 15% (Grade I) ($P = 0.026$). Singh *et al.*^[17] investigated in a non-randomized comparative study the efficacy of a higher dosage of intrarectal amifostine (2 g) vs a lower dosage (1 g). After assigning 18 patients to 1 g and 12 patients to 2 g, the authors found that patients treated with higher dosage did not experience radiation-related toxicity, while 33% of patients in the 1-g group reported Grade 2 toxicity; however, the difference was not statistically significant ($P = 0.06$)^[17].

The intrarectal route of administration of amifostine turned out to be more effective than the subcutaneous one^[13]. Kouloulis *et al.*^[13] investigated in a randomized comparative study 27 patients treated with daily intrarectal amifostine at a dose of 1.5 g vs 26 patients treated with daily subcutaneous amifostine at a dose of 500 mg and found a lower incidence of Grades I–II rectal radiation morbidity in the intrarectal group (11% vs 42%, $P = 0.04$)^[13].

Effect on chronic PRD: The efficacy of amifostine preventive treatment on late-onset, chronic pelvic

radiation disease is still unclear and data conflicting. One pilot study, based on 29 patients with localized prostate cancer, showed a significant reduction of late rectal bleeding after daily intrarectal high-dosage amifostine (1.5-2.5 g) vs low-dosage amifostine (0.5-1 g) ($P = 0.0325$)^[18]. Singh *et al*^[17] in a non-randomized, controlled study considered 30 patients with pelvic cancer, 18 of whom received low-dosage intrarectal amifostine (1 g daily) vs 12 patients receiving high-dosage intrarectal amifostine (2 g daily) and found that the higher dosage significantly reduced late-onset, chronic pelvic radiation disease at 12 mo ($P = 0.04$). On the other hand, Katsanos *et al*^[15] in the previously mentioned randomized controlled trial did not report any efficacy for subcutaneous amifostine to prevent late-onset toxicity. Based on the available data, it is not clear whether the administration route influences the efficacy of amifostine-based preventive treatment. Well-performed, prospective, large sample trials, comparing different routes of administration should be performed to clarify the effect on late-onset radiation-induced toxicity.

Amifostine can be considered as a safe drug and side effects have been described only when the intravenous and subcutaneous routes of administration were performed. Nausea, vomiting, severe asthenia, transient hypotension and local erythema and pruritus have been the most frequently reported side effects (5.5%-27.8%)^[15,19]. Infrequently, severe hypotension and systemic allergic reaction with cutaneous rash and dyspnea have been described^[14]. No life-threatening adverse events have ever been reported. Notably, intrarectal amifostine seems to be safer and systemic side effects have not been reported since now.

Aminosalicylates

Aminosalicylates are compounds that contain 5-aminosalicylic acid (5-ASA), which is a potent inhibitor of the synthesis and release of pro-inflammatory mediators (e.g., nitric oxide, leukotrienes, thromboxanes, and platelet activating factor) and also inhibits the function of several cells implicated in the acute inflammatory and immune response (e.g., natural killer cells, mast cells, neutrophils, mucosal lymphocytes, and macrophages)^[20]. As the pathophysiology of early pelvic radiation disease is mainly mediated by eicosanoid inflammatory mediators^[21], the administration of aminosalicylates in order to prevent acute radiation-induced rectal injury has been investigated.

The available aminosalicylates can be distinguished into pro-drugs (sulfasalazine and balsalazide) and active compound (mesalazine).

Sulfasalazine

Sulfasalazine is a pro-drug that is metabolized to its active component, 5-ASA, by intestinal microflora,

therefore ensuring a high concentration of the active drug to the distal colon.

Kiliç *et al*^[22] considered in a randomized, placebo-controlled, double-blind trial, 87 patients, 44 of whom were assigned to the active group (two tablets of 500 mg of sulfasalazine twice a day) against 43 patients allocated in the control group. During irradiation, diarrhea occurred in 55% of the sulfasalazine and 86% of the placebo group, and this difference was found to be statistically significant ($P < 0.001$)^[22]. Additionally, sulfasalazine significantly decreased the severity of radiation-induced symptoms as evaluated by LENT-SOMA score after the first week of radiotherapy: precisely, in the second ($P = 0.003$), third ($P < 0.001$), fourth ($P < 0.001$) and fifth ($P < 0.001$) weeks.

Pal *et al*^[23] enrolled in a randomized, placebo-controlled trial 98 patients with carcinoma of the cervix, 49 of whom were assigned to the active arm (oral sulfasalazine 1 g twice daily from the day of starting of radiotherapy to 1 wk after completion of treatment) vs 49 patients allocated to the placebo group. Sulfasalazine showed to significantly reduce the occurrence of acute radiation-induced toxicity as evaluated by Common Toxicity Criteria (CTC); the incidence of grade II or higher gastrointestinal toxicity was 19.1% (9/47) in the active arm vs 41.7% (20/48) in the control group ($P = 0.017$). None of the previously cited trials reported any considerable side effect due to sulfasalazine.

Most of the existing evidence supports the role of sulfasalazine as a preventive treatment of acute, early-onset PRD. The Mucositis Study Group of Multinational Association of Supportive Care in Cancer (MASCC), an international multidisciplinary organization dedicated to research, policy and programs to improve the quality of life of patients and caregivers touched by cancer^[24], suggests the use of sulfasalazine orally twice daily to reduce the incidence and severity of radiation-induced enteropathy in patients receiving external-beam radiotherapy to the pelvis^[25]. However, there are no definitive data on its long-term efficacy in the prevention of chronic PRD.

Balsalazide

Balsalazide is a pro-drug of mesalazine chemically similar to sulfasalazine but lacking the sulfapyridine moiety in favor of a less antigenic carrier, 4-aminobenzoyl- β -alanine, which yields a high concentration of active drug (5-ASA) to the distal colon being metabolized by colonic microflora^[20].

Jahraus *et al*^[26] performed the only randomized, placebo-controlled, double-blind trial aiming to evaluate the preventive effect of balsalazide on acute radiation-induced side effects. Twenty five patients were enrolled and randomized to active treatment (3 capsules of 750 mg of balsalazide 2 times a day) or to identical-looking placebo. Patients started drugs

or placebo intake 5 d before the beginning of the radiation treatment and continued it until 14 d after the completion of RT. After a follow-up conducted throughout RT and concluded 2 wk after the end of radiation treatment, balsalazide significantly reduced the frequency of acute radiation-induced pelvic disease ($P = 0.04$) according to the CTC scale, in particular of proctopathy symptoms, when compared to placebo. Of note, 3 patients in the balsalazide group and 1 patient in the placebo group withdrew from the trial, because of the high number of pills to intake, thus the proposed way of administration might affect patient compliance in the clinical practice. Nausea and limited vomiting are the only adverse reactions to balsalazide reported so far^[26].

Up to now, these data have not been confirmed by further investigational trials, and the efficacy of balsalazide for the prevention of late-onset pelvic radiation disease has not yet been evaluated.

Mesalazine

Mesalazine (5-ASA) is the active compound of aminosaliclates. Freund *et al*^[27] considered in a randomized, placebo-controlled trial 16 patients with prostate cancer, 8 of whom received mesalazine as rectal suppositories (250 mg three times a day) vs 8 patients assigned to the placebo arm. The study was prematurely stopped because of severe side effects in the 5-ASA group: 75% of patients treated with 5-ASA reported symptoms of severe proctopathy while only one patient in the placebo group. Additionally, Baughan *et al*^[28] enrolled in a randomized controlled trial 73 patients with pelvic cancer and found that diarrhea occurred in a higher proportion of patients in the 5-ASA arm than the placebo arm (91.2% vs 73.7%, $P = 0.01$). Resbeut *et al*^[29] considered in a randomized, placebo-controlled trial 153 patients, 74 of whom receiving two tablets four times a day of mesalazine 500 mg (daily dose 4 g) vs 79 patients assigned to the placebo arm throughout the pelvic irradiation period. No significant difference regarding either the occurrence and the duration of diarrhea was observed, while the severity of diarrhea considered after two weeks from the beginning of radiation therapy was significantly higher in the 5-ASA group ($P = 0.006$).

Based on the available evidences, there is no evidence supporting the administration of mesalazine in the prevention of acute, early-onset PRD. Moreover mesalazine has repeatedly shown in RCTs to worsen symptoms in comparison with placebo and thus mesalazine should be avoided as a preventive agent.

Beclomethasone dipropionate

The inflammatory process plays a pivotal role in the early phases of radiation-induced damages^[3]. Therefore, reducing or abolishing the initial infl-

ammatory process could be a reasonable preventive strategy of radiation-induced alterations. Glucocorticosteroids are the most effective anti-inflammatory agents available for several inflammatory diseases, but their prolonged use is limited by the development of severe side effects. Beclomethasone dipropionate (BDP) is a nonsystemic glucocorticoid with a different and safer pharmacokinetic profile.

In 2011, the preventive efficacy of BDP has been investigated in a double-blind, placebo-controlled randomized trial^[30]. Patients with a diagnosis of prostate cancer and scheduled for radiation treatment were treated with a 3-mg BDP enema or identical-looking placebo the evening before each radiation session, for the entire duration of radiotherapy. Immediately after the end of radiotherapy, patients stopped the enema formulation and received two 3-mg BDP suppositories, or identical placebo, for 4 more weeks. Between June 2007 and October 2008, 120 patients were randomized, 60 patients in the BDP arm and 60 patients in the placebo arm. After 12 mo of follow-up, patients treated with BDP presented a significant reduction of the post-radiation risk of bleeding (OR = 0.38; 95%CI: 0.17-0.86) and of rectal mucosal changes. In particular, actively treated patients presented fewer rectal angiectasias in comparison to non-treated patients. Most importantly, at the end of follow-up, patients on BDP presented a higher Quality of Life score, in particular BDP preventive treatment seemed to better preserve the patient's emotional status (e.g., anger, depression, irritability), which was less frequently altered.

At the moment, this represents the only available RCT showing a beneficial effect of BDP treatment as chemopreventive agent. Further studies are warranted to confirm these encouraging results.

Misoprostol

Misoprostol is a methylester analog of prostaglandin E1 that is used to prevent gastric ulcers, to treat missed miscarriage, to induce labor and to induce abortion. The rationale for its use as a radioprotective agent lies on its capability to stimulate mucus production, to prevent cellular shedding and lysosomal enzyme release^[31]. Additionally, misoprostol seems to induce the production of sulfhydryl compounds, which may act as free radical scavengers^[32].

Few randomized trials have investigated the efficacy of intrarectal misoprostol in preventing PRD and overall the results are contrasting. Khan *et al*^[33] enrolled in a randomized, placebo-controlled, double-blind trial, 16 patients who underwent pelvic irradiation, 9 of whom received one rectal suppository of 400 µg of misoprostol one hour before each radiotherapy session, vs 7 patients taking placebo. According to a non-validated clinical scale-considering bowel movements per day, rectal tenesmus, rectal bleeding and general well-being-misoprostol significantly reduced the occurrence and

severity of acute, early-onset PRD ($P < 0.01$) and also decreased the incidence and severity of chronic rectal toxicity ($P < 0.01$). On the other hand, Hille *et al* randomized 100 patients with prostatic cancer, 50 of whom received one rectal suppository of 400 µg of misoprostol one hour before each radiotherapy session, vs 50 patients taking placebo^[34,35]. As assessed by the validated RTOG and LENT/SOMA clinical scales, misoprostol did not reduce the incidence and severity of radiation-induced acute PRD nor the occurrence and gravity of chronic, late-onset PRD. Furthermore, misoprostol increased the incidence of grade 1 and 2 acute rectal bleeding ($P = 0.03$) and also favored late rectal bleeding.

In conclusion, as the existing evidence concerning the efficacy of misoprostol in the prevention of PRD is conflicting, misoprostol should not be considered as a treatment of choice in the clinical setting, as also discouraged by the MASCC panel^[25].

Sucralfate

Sucralfate is an alkaline aluminum hydroxide of sulfated sucrose. The rationale for the administration of sucralfate in the prevention of PRD lies on its supposed property to protect mucosa by forming a viscous superficial coating and to stimulate mucosal healing by its angiogenic effect^[36,37]. Sucralfate can be administered either orally or as a rectal enema.

Effect on acute PRD: The efficacy of sucralfate in the prevention of acute, early-onset PRD has been investigated by several randomized, controlled trials^[38-42]. Overall, sucralfate as a preventive treatment on acute radiation-induced toxicity seems not to be effective.

In 1991, Henriksson *et al*^[38] published a randomized, double-blind placebo-controlled trial based on 66 patients with localized pelvic cancer and found encouraging results; indeed, 1 g of sucralfate taken 6 times a day significantly improved diarrhea ($P = 0.003$), frequency of defecation ($P = 0.04$), stool consistency ($P = 0.04$) and loperamide consumption ($P = 0.003$) as evaluated by patient diary. However, these data were not subsequently confirmed by several RCTs. Martenson *et al*^[39] enrolled in a randomized double-blind placebo-controlled trial 123 patients with pelvic cancer, 62 receiving oral sucralfate 1.5 g four times a day vs 61 receiving placebo, and found that sucralfate did not decrease acute pelvic RT-related bowel toxicity and even seemed to worsen some gastrointestinal symptoms. Indeed, patients receiving sucralfate had an increased frequency of fecal incontinence (34% vs 16%, $P = 0.04$), need for protective clothing (23% vs 8%, $P = 0.04$), and an increased occurrence and severity of nausea ($P = 0.03$). Similarly, Stellamans *et al*^[40] evaluated in a randomized double-blind placebo-controlled trial 80 patients, 38 of whom received oral sucralfate four times a day, twice 1 g and twice 2 g

vs 42 patients taking placebo, and did not find any significant difference in the incidence and severity of acute radiotherapy-induced discomfort, diarrhea and in the number of stools per day. Moreover, Hovdenak *et al*^[41] enrolled in a randomized, placebo-controlled trial 51 patients with localized pelvic tumor during 7-wk radiotherapy, 24 of whom were randomized to oral sucralfate 2 g three times a day vs 27 receiving placebo, and found in an interim analysis that sucralfate significantly increased acute RT-induced diarrhea ($P = 0.033$) so that the trial was stopped. The finding of the above mentioned RCTs was further confirmed by a meta-analysis that showed no significant beneficial effect of sucralfate on the prevention of acute radiation-induced symptoms^[41]. The rectal administration of sucralfate was tested too. In a randomized, placebo-controlled trial, O'Brien *et al*^[42] enrolled 86 patients with localized prostate cancer and assigned 43 of them to receive once daily enema of 3 g of sucralfate in 15 mL suspension, given during and for 2 wk after the end of radiotherapy vs 43 patients receiving placebo, and found that sucralfate did not substantially reduce the incidence of symptoms associated with irradiation.

Based on the available evidences, the MASCC panel recommends oral sucralfate not to be used to prevent acute rectal side effects induced by radiotherapy^[25].

Effect on chronic PRD: As far as chronic, late-onset PRD is concerned, its prevention with oral sucralfate has been investigated in several randomized controlled trials with conflicting results. In the previously reported trial, Henriksson *et al*^[43] found that 1 g of sucralfate taken 6 times a day was again significantly effective in reducing the frequency of defecation ($P = 0.01$), of mucus discharge ($P = 0.01$) and weight loss ($P = 0.04$) in comparison to the placebo group, and also observed a trend in diminishing the occurrence of blood in the stools ($P = 0.11$) and loperamide consumption ($P = 0.11$). At opposite, Kneebone *et al*^[44] evaluated in a randomized, double-blind placebo-controlled trial 298 patients with localized prostate cancer, 143 of whom received 3 g of oral sucralfate twice a day vs 155 patients taking placebo, and found no significant reduction in the incidence of late rectal toxicity in patients receiving sucralfate; indeed, the cumulative incidence of RTOG Grade 2 or worse late rectal toxicity at 2 years, was 28% for placebo and 22% for the sucralfate arm ($P = 0.23$) and there were no differences concerning bowel frequency ($P = 0.99$), mucus discharge ($P = 0.64$), or fecal incontinence ($P = 0.90$)^[44].

O'Brien *et al*^[45] enrolled in a randomized, placebo-controlled trial 86 patients with localized prostate cancer and assigned 43 of them to receive once daily enema of 3 g of sucralfate in 15 mL suspension vs 43 receiving placebo and found that rectal

sucralfate did not reduce the occurrence of chronic PRD, as the occurrence of late Grade 2 RTOG/EORTC toxicity was 5% in the sucralfate arm vs 12% in the placebo group ($P = 0.26$), and the incidence of late rectal bleeding was not different between the two arms of randomization (54% for sucralfate vs 59% for placebo).

Concerning the existing evidence, sucralfate seems to be safe and no serious adverse events have been reported. Fecal incontinence, nausea and constipation are the only side effects reported so far, in about 15%-34% of patients^[39,41].

Probiotic supplementation

After pelvic radiation treatment it has been observed a change in the microbial ecosystem of the large intestine, which can contribute to the development of radiation-induced GI side effects^[46,47]. Therefore, it has been suggested that probiotics supplementation during radiation treatment might reduce the development of radiation-induced side effects, in particular of diarrhea. Indeed, probiotics might have a role in the prevention and treatment of radiation-induced diarrhea, because their mechanisms of action include modification of composition of indigenous intestinal flora, enhancement of mucosal barrier function, prevention of bacterial overgrowth, and colonization of pathogens, and stimulation of hosts immune defenses^[48].

Up to now, only few studies have been performed with the intent to ascertain the preventive effect of probiotics supplementation during radiation-treatment^[49,50]. Overall, these studies have concluded for a possible preventive effect. In particular Fuccio *et al.*^[50] performed a double-blinded, placebo-controlled trial to investigate whether a preparation of probiotics, VSL#3, could reduce the incidence and severity of radiation-induced diarrhea. Each sachet of VSL#3 administered during the trial contained 450 billions/g of viable lyophilized bacteria, including several different strains of lactobacilli (*L. casei*, *L. plantarum*, *L. acidophilus*, *L. delbruekii* subsp. *bulgaricus*), 3 strains of bifidobacteria (*B. longum*, *B. breve* and *B. infantis*) and 1 strain of *Streptococcus salivarius* subsp. *thermophilus*. During a 6-year period of enrollment, 482 patients who underwent adjuvant postoperative radiation therapy for sigmoid, rectal or cervical cancers were evaluated; 243 patients were randomized to receive probiotic supplementation and 239 patients were randomized in the placebo group. Radiation-induced diarrhea was less frequent in the active group (31.6% of patients) than in the placebo group (51.8%) ($P < 0.001$); furthermore, diarrhea was also consistently less severe in the probiotic supplementation group. Indeed, in the placebo group, 55.4% of patients that developed diarrhea presented a grade 3 severity (requiring treatment) or 4 (presence of hemorrhage or dehydration), compared with only 1.4% of patients in the active group (P

< 0.001). Finally, the mean daily number of bowel movements was significantly lower in the active group compared with the placebo group ($P < 0.001$), whereas the mean time of use of rescue medication (loperamide) was significantly longer ($P < 0.001$). Finally, probiotic supplementation was well tolerated without reporting moderate or severe side effects.

These encouraging results, however, have not yet been confirmed and further well-performed, high-quality studies should be performed on this highly interesting issue.

CONCLUSION

Pelvic radiation disease is a multifactorial disease with a wide range of clinical spectrum. Several risk factors and subgroups of patients at increased risk of developing radiation-induced toxicity have been identified. Since endothelial dysfunction, inflammation, and connective tissue alterations have an important role in the pathogenesis of pelvic radiation disease^[3], patients with diabetes, inflammatory bowel diseases (Crohn's disease or ulcerative colitis), and collagen vascular disease (scleroderma, systemic lupus erythematosus) have an increased risk of developing severe acute and late toxicities. Patients with these clinical conditions might have the maximum beneficial effect from a preventive treatment with several agents (e.g., intrarectal amifostine, beclomethasone dipropionate and oral probiotics), for which well-performed RCTs have showed a beneficial effect for the prevention of acute and/or late-onset radiation-induced toxicities. Further studies should be performed to increase the literature concerning this issue, focusing on the identification of subgroups of patients for which a preventive strategy should be advised.

REFERENCES

- 1 Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin* 2011; **61**: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]
- 2 Andreyev HJ, Wotherspoon A, Denham JW, Hauer-Jensen M. Defining pelvic-radiation disease for the survivorship era. *Lancet Oncol* 2010; **11**: 310-312 [PMID: 20149738 DOI: 10.1016/S1470-2045(10)70026-7]
- 3 Fuccio L, Guido A, Andreyev HJ. Management of intestinal complications in patients with pelvic radiation disease. *Clin Gastroenterol Hepatol* 2012; **10**: 1326-1334.e4 [PMID: 22858731 DOI: 10.1016/j.cgh.2012.07.017]
- 4 Staffurth J. A review of the clinical evidence for intensity-modulated radiotherapy. *Clin Oncol (R Coll Radiol)* 2010; **22**: 643-657 [PMID: 20673708 DOI: 10.1016/j.clon.2010.06.013]
- 5 Dearnaley DP, Khoo VS, Norman AR, Meyer L, Nahum A, Tait D, Yarnold J, Horwich A. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. *Lancet* 1999; **353**: 267-272 [PMID: 9929018 DOI: 10.1016/S0140-6736(98)05180-0]
- 6 Putta S, Andreyev HJ. Faecal incontinence: A late side-effect of pelvic radiotherapy. *Clin Oncol (R Coll Radiol)* 2005; **17**: 469-477 [PMID: 16149292 DOI: 10.1016/j.clon.2005.02.008]
- 7 Denham JW, Hauer-Jensen M. The radiotherapeutic injury--a

- complex 'wound'. *Radiother Oncol* 2002; **63**: 129-145 [PMID: 12063002 DOI: 10.1016/S0167-8140(02)00060-9]
- 8 **Brenn T**, Fletcher CD. Postirradiation vascular proliferations: an increasing problem. *Histopathology* 2006; **48**: 106-114 [PMID: 16359542 DOI: 10.1111/j.1365-2559.2005.02293.x]
- 9 **Dörr W**, Hendry JH. Consequential late effects in normal tissues. *Radiother Oncol* 2001; **61**: 223-231 [PMID: 11730991 DOI: 10.1016/S0167-8140(01)00429-7]
- 10 **Wedlake LJ**, Thomas K, Lalji A, Blake P, Khoo VS, Tait D, Andreyev HJ. Predicting late effects of pelvic radiotherapy: is there a better approach? *Int J Radiat Oncol Biol Phys* 2010; **78**: 1163-1170 [PMID: 20231077 DOI: 10.1016/j.ijrobp.2009.09.011]
- 11 **Schumacher C**, Paul K, Robbe Y, Sicart MT, Chanal JL, Delard R, Dubois JB. Mice's rectum radioprotection: comparative efficacy of a series of aminothiols and aminothiol precursors. *Farmaco* 1997; **52**: 729-731 [PMID: 9648277]
- 12 **Keshavarzian A**, Haydek J, Zabihi R, Doria M, D'Astice M, Sorenson JR. Agents capable of eliminating reactive oxygen species. Catalase, WR-2721, or Cu(II)2(3,5-DIPS)4 decrease experimental colitis. *Dig Dis Sci* 1992; **37**: 1866-1873 [PMID: 1335406 DOI: 10.1007/BF01308081]
- 13 **Kouloulis VE**, Kouvaris JR, Pissakas G, Mallas E, Antypas C, Kokakis JD, Matsopoulos G, Michopoulos S, Mystakidou K, Vlahos LJ. Phase II multicenter randomized study of amifostine for prevention of acute radiation rectal toxicity: topical intrarectal versus subcutaneous application. *Int J Radiat Oncol Biol Phys* 2005; **62**: 486-493 [PMID: 15890591 DOI: 10.1016/j.ijrobp.2004.10.043]
- 14 **Athanassiou H**, Antonadou D, Coliarakis N, Kouveli A, Synodinou M, Paraskevaidis M, Sarris G, Georgakopoulos GR, Panousaki K, Karageorgis P, Throuvalas N. Protective effect of amifostine during fractionated radiotherapy in patients with pelvic carcinomas: results of a randomized trial. *Int J Radiat Oncol Biol Phys* 2003; **56**: 1154-1160 [PMID: 12829154 DOI: 10.1016/S0360-3016(03)00187-1]
- 15 **Katsanos KH**, Briassoulis E, Tsekeris P, Batistatou A, Bai M, Tolis C, Capizzello A, Pangelos I, Karavasilis V, Christodoulou D, Tsianos EV. Randomized phase II exploratory study of prophylactic amifostine in cancer patients who receive radical radiotherapy to the pelvis. *J Exp Clin Cancer Res* 2010; **29**: 68 [PMID: 20537164 DOI: 10.1186/1756-9966-29-68]
- 16 **Kouloulis VE**, Kouvaris JR, Pissakas G, Kokakis JD, Antypas C, Mallas E, Matsopoulos G, Michopoulos S, Vosdoganis SP, Kostakopoulos A, Vlahos LJ. A phase II randomized study of topical intrarectal administration of amifostine for the prevention of acute radiation-induced rectal toxicity. *Strahlenther Onkol* 2004; **180**: 557-562 [PMID: 15378186 DOI: 10.1007/s00066-004-1226-1]
- 17 **Singh AK**, Ménard C, Guion P, Simone NL, Smith S, Crouse NS, Godette DJ, Cooley-Zgela T, Sciuto LC, Coleman J, Pinto P, Albert PS, Camphausen K, Coleman CN. Intrarectal amifostine suspension may protect against acute proctitis during radiation therapy for prostate cancer: a pilot study. *Int J Radiat Oncol Biol Phys* 2006; **65**: 1008-1013 [PMID: 16730138 DOI: 10.1016/j.ijrobp.2006.02.030]
- 18 **Ben-Josef E**, Han S, Tobin M, Shaw LM, Bonner HS, Vargas BJ, Prokop S, Stamos B, Kelly L, Biggar S, Kaplan I. A pilot study of topical intrarectal application of amifostine for prevention of late radiation rectal injury. *Int J Radiat Oncol Biol Phys* 2002; **53**: 1160-1164 [PMID: 12128116 DOI: 10.1016/S0360-3016(02)02883-3]
- 19 **Kouvaris J**, Kouloulis V, Malas E, Antypas C, Kokakis J, Michopoulos S, Matsopoulos G, Vlahos L. Amifostine as radioprotective agent for the rectal mucosa during irradiation of pelvic tumors. A phase II randomized study using various toxicity scales and rectosigmoidoscopy. *Strahlenther Onkol* 2003; **179**: 167-174 [PMID: 12627259 DOI: 10.1007/s00066-003-0970-y]
- 20 **Prakash A**, Spencer CM. Balsalazide. *Drugs* 1998; **56**: 83-89; discussion 90 [PMID: 9664201 DOI: 10.2165/00003495-199856010-00008]
- 21 **Cole AT**, Slater K, Sokal M, Hawkey CJ. In vivo rectal inflammatory mediator changes with radiotherapy to the pelvis. *Gut* 1993; **34**: 1210-1214 [PMID: 8406156 DOI: 10.1136/gut.34.9.1210]
- 22 **Kiliç D**, Egehan I, Ozenirler S, Dursun A. Double-blinded, randomized, placebo-controlled study to evaluate the effectiveness of sulphasalazine in preventing acute gastrointestinal complications due to radiotherapy. *Radiother Oncol* 2000; **57**: 125-129 [PMID: 11054515 DOI: 10.1016/S0167-8140(00)00254-1]
- 23 **Pal S**, Adhikary SS, Bhattacharya B, Basu J, Ghosh T, Patra NB. A prospective randomized controlled trial to study the role of sulfasalazine in prevention of acute gastrointestinal toxicity associated with concurrent chemoradiation in carcinoma cervix. *Clin Cancer Investig J* 2013; **2**: 118-121 [DOI: 10.4103/2278-0513.113633]
- 24 **Rittenberg CN**, Johnson JL, Kuncio GM. An oral history of MASCC, its origin and development from MASCC's beginnings to 2009. *Support Care Cancer* 2010; **18**: 775-784 [PMID: 20221642]
- 25 **Gibson RJ**, Keefe DM, Lalla RV, Bateman E, Blijlevens N, Fijlstra M, King EE, Stringer AM, van der Velden WJ, Yazbeck R, Elad S, Bowen JM. Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. *Support Care Cancer* 2013; **21**: 313-326 [PMID: 23142924 DOI: 10.1007/s00520-012-1644-z]
- 26 **Jahraus CD**, Bettenhausen D, Malik U, Sellitti M, St Clair WH. Prevention of acute radiation-induced proctosigmoiditis by balsalazide: a randomized, double-blind, placebo controlled trial in prostate cancer patients. *Int J Radiat Oncol Biol Phys* 2005; **63**: 1483-1487 [PMID: 16099600 DOI: 10.1016/j.ijrobp.2005.04.032]
- 27 **Freund U**, Schölmerich J, Siems H, Kluge F, Schäfer HE, Wannenmacher M. [Unwanted side-effects in using mesalazine (5-aminosalicylic acid) during radiotherapy]. *Strahlenther Onkol* 1987; **163**: 678-680 [PMID: 3313776]
- 28 **Baughan CA**, Canney PA, Buchanan RB, Pickering RM. A randomized trial to assess the efficacy of 5-aminosalicylic acid for the prevention of radiation enteritis. *Clin Oncol (R Coll Radiol)* 1993; **5**: 19-24 [PMID: 8424910 DOI: 10.1016/S0936-6555(05)80689-2]
- 29 **Resbeut M**, Marteau P, Cowen D, Richaud P, Bourdin S, Dubois JB, Mere P, N'Guyen TD. A randomized double blind placebo controlled multicenter study of mesalazine for the prevention of acute radiation enteritis. *Radiother Oncol* 1997; **44**: 59-63 [PMID: 9288859]
- 30 **Fuccio L**, Guido A, Laterza L, Eusebi LH, Busutti L, Bunkheila F, Barbieri E, Bazzoli F. Randomised clinical trial: preventive treatment with topical rectal beclomethasone dipropionate reduces post-radiation risk of bleeding in patients irradiated for prostate cancer. *Aliment Pharmacol Ther* 2011; **34**: 628-637 [PMID: 21790680 DOI: 10.1111/j.1365-2036.2011.04780.x]
- 31 **Hanson WR**, Houseman KA, Collins PW. Radiation protection in vivo by prostaglandins and related compounds of the arachidonic acid cascade. *Pharmacol Ther* 1988; **39**: 347-356 [PMID: 2849133 DOI: 10.1016/0163-7258(88)90082-4]
- 32 **Gal D**, Strickland DM, Lifshitz S, Buchsbaum HJ, Mitchell MD. Effect of radiation on prostaglandin production by human bowel in vitro. *Int J Radiat Oncol Biol Phys* 1984; **10**: 653-657 [PMID: 6588048]
- 33 **Khan AM**, Birk JW, Anderson JC, Georgsson M, Park TL, Smith CJ, Comer GM. A prospective randomized placebo-controlled double-blinded pilot study of misoprostol rectal suppositories in the prevention of acute and chronic radiation proctitis symptoms in prostate cancer patients. *Am J Gastroenterol* 2000; **95**: 1961-1966 [PMID: 10950043 DOI: 10.1111/j.1572-0241.2000.02260.x]
- 34 **Hille A**, Schmidberger H, Hermann RM, Christiansen H, Saile B, Pradier O, Hess CF. A phase III randomized, placebo-controlled, double-blind study of misoprostol rectal suppositories to prevent acute radiation proctitis in patients with prostate cancer. *Int J Radiat Oncol Biol Phys* 2005; **63**: 1488-1493 [PMID: 16137837 DOI: 10.1016/j.ijrobp.2005.05.063]
- 35 **Kertesz T**, Herrmann MK, Zapf A, Christiansen H, Hermann RM, Pradier O, Schmidberger H, Hess CF, Hille A. Effect of a prostaglandin--given rectally for prevention of radiation-induced acute proctitis--on late rectal toxicity. Results of a phase III randomized, placebo-controlled, double-blind study. *Strahlenther Onkol* 2009; **185**: 596-602 [PMID: 19756426 DOI: 10.1007/s00066-009-1978-8]
- 36 **Folkman J**, Shing Y. Control of angiogenesis by heparin and other sulfated polysaccharides. *Adv Exp Med Biol* 1992; **313**: 355-364

- [PMID: 1279952]
- 37 **Szabo S**, Vattay P, Scarbrough E, Folkman J. Role of vascular factors, including angiogenesis, in the mechanisms of action of sucralfate. *Am J Med* 1991; **91**: 158S-160S [PMID: 1715670 DOI: 10.1016/0002-9343(91)90469-E]
 - 38 **Henriksson R**, Franzén L, Littbrand B. Prevention of irradiation-induced bowel discomfort by sucralfate: a double-blind, placebo-controlled study when treating localized pelvic cancer. *Am J Med* 1991; **91**: 151S-157S [PMID: 1882903 DOI: 10.1016/0002-9343(91)90468-D]
 - 39 **Martenson JA**, Bollinger JW, Sloan JA, Novotny PJ, Urias RE, Michalak JC, Shanahan TG, Mailliard JA, Levitt R. Sucralfate in the prevention of treatment-induced diarrhea in patients receiving pelvic radiation therapy: A North Central Cancer Treatment Group phase III double-blind placebo-controlled trial. *J Clin Oncol* 2000; **18**: 1239-1245 [PMID: 10715293]
 - 40 **Stellamans K**, Lievens Y, Lambin P, Van den Weyngaert D, Van den Bogaert W, Scalliet P, Hutsebaut L, Haustermans K. Does sucralfate reduce early side effects of pelvic radiation? A double-blind randomized trial. *Radiother Oncol* 2002; **65**: 105-108 [PMID: 12443806 DOI: 10.1016/S0167-8140(02)00281-5]
 - 41 **Hovdenak N**, Sørbye H, Dahl O. Sucralfate does not ameliorate acute radiation proctitis: randomised study and meta-analysis. *Clin Oncol (R Coll Radiol)* 2005; **17**: 485-491 [PMID: 16149294 DOI: 10.1016/j.clon.2005.04.011]
 - 42 **O'Brien PC**, Franklin CI, Dear KB, Hamilton CC, Poulsen M, Joseph DJ, Spry N, Denham JW. A phase III double-blind randomised study of rectal sucralfate suspension in the prevention of acute radiation proctitis. *Radiother Oncol* 1997; **45**: 117-123 [PMID: 9424000 DOI: 10.1016/S0167-8140(97)00146-1]
 - 43 **Henriksson R**, Franzén L, Littbrand B. Effects of sucralfate on acute and late bowel discomfort following radiotherapy of pelvic cancer. *J Clin Oncol* 1992; **10**: 969-975 [PMID: 1588377]
 - 44 **Kneebone A**, Mameghan H, Bolin T, Berry M, Turner S, Kearsley J, Graham P, Fisher R, Delaney G. Effect of oral sucralfate on late rectal injury associated with radiotherapy for prostate cancer: A double-blind, randomized trial. *Int J Radiat Oncol Biol Phys* 2004; **60**: 1088-1097 [PMID: 15519779 DOI: 10.1016/j.ijrobp.2004.04.033]
 - 45 **O'Brien PC**, Franklin CI, Poulsen MG, Joseph DJ, Spry NS, Denham JW. Acute symptoms, not rectally administered sucralfate, predict for late radiation proctitis: longer term follow-up of a phase III trial--Trans-Tasman Radiation Oncology Group. *Int J Radiat Oncol Biol Phys* 2002; **54**: 442-449 [PMID: 12243820 DOI: 10.1016/S0360-3016(02)02931-0]
 - 46 **Husebye E**, Skar V, Høverstad T, Iversen T, Melby K. Abnormal intestinal motor patterns explain enteric colonization with gram-negative bacilli in late radiation enteropathy. *Gastroenterology* 1995; **109**: 1078-1089 [PMID: 7557072 DOI: 10.1016/0016-5085(95)90565-0]
 - 47 **Manichanh C**, Varela E, Martinez C, Antolin M, Llopis M, Doré J, Giral J, Guarner F, Malagelada JR. The gut microbiota predispose to the pathophysiology of acute postradiotherapy diarrhea. *Am J Gastroenterol* 2008; **103**: 1754-1761 [PMID: 18564125 DOI: 10.1111/j.1572-0241.2008.01868.x]
 - 48 **Guarner F**, Malagelada JR. Gut flora in health and disease. *Lancet* 2003; **361**: 512-519 [PMID: 12583961]
 - 49 **Delia P**, Sansotta G, Donato V, Frosina P, Messina G, De Renzis C, Famularo G. Use of probiotics for prevention of radiation-induced diarrhea. *World J Gastroenterol* 2007; **13**: 912-915 [PMID: 17352022]
 - 50 **Fuccio L**, Guido A, Eusebi LH, Laterza L, Grilli D, Cennamo V, Ceroni L, Barbieri E, Bazzoli F. Effects of probiotics for the prevention and treatment of radiation-induced diarrhea. *J Clin Gastroenterol* 2009; **43**: 506-513 [PMID: 19398930 DOI: 10.1097/MCG.0b013e3181a1f59c]

P- Reviewer: Jain S S- Editor: Song XX L- Editor: A
E- Editor: Lu YJ





Published by **Baishideng Publishing Group Inc**

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

Help Desk: <http://www.wjgnet.com/esps/helpdesk.aspx>

<http://www.wjgnet.com>

